MedPath

MICRO LABS LIMITED

🇮🇳India
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

36

Active:0
Completed:20

Trial Phases

4 Phases

Phase 2:1
Phase 3:12
Phase 4:12
+1 more phases

Drug Approvals

263

PHILIPPINES:179
FDA:72
CANADA:6

Drug Approvals

AMOXICILLIN AND CLAVULANATE POTASSIUM

Approval Date
Mar 29, 2024
FDA

BIMATOPROST

Approval Date
Mar 22, 2024
FDA

Clobazam

Approval Date
Mar 20, 2024
FDA

LEVETIRACETAM

Approval Date
Mar 19, 2024
FDA

BUPROPION HYDROCHLORIDE

Approval Date
Feb 24, 2024
FDA

CROMOLYN SODIUM

Approval Date
Feb 13, 2024
FDA

AMOXICILLIN

Approval Date
Feb 5, 2024
FDA

Pirfenidone

Approval Date
Feb 2, 2024
FDA

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

Approval Date
Dec 27, 2023
FDA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 8
  • Next

Clinical Trials

Distribution across different clinical trial phases (35 trials with phase data)• Click on a phase to view related trials

Phase 3
12 (34.3%)
Phase 4
12 (34.3%)
Not Applicable
9 (25.7%)
Phase 2
1 (2.9%)
phase_2_3
1 (2.9%)
No trials found

News

Esperion Secures Patent Protection for NEXLETOL Until 2040 Through Settlement with Micro Labs

Esperion Therapeutics has reached a settlement agreement with Micro Labs that prevents the generic manufacturer from marketing a version of NEXLETOL (bempedoic acid) before April 19, 2040.

Allchem Lifescience Files for IPO to Raise ₹190 Crore, Expands API Manufacturing Capabilities

Gujarat-based Allchem Lifescience has filed preliminary IPO papers with SEBI, seeking to raise ₹190 crore through fresh equity shares and an offer for sale of 71.55 lakh shares by promoters.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.